
Fresenius Medical Care AG & Co. KGaA
FMSNYSEHealthcareMedical - Care Facilities
Previous close
$23.43
$0.00 · 0.00%
FMS company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
89
Deep Value
Momentum
43
Neutral
Sentiment
48
Mixed
Risk resilience
71
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteFresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- Headquarters
- DE
- CEO
- Helen Giza
- Listed since
- Sep 17, 1996
- Employees
- 108,165
Market position
Day range
Current $23.43
52-week range
Current $23.43
- Open
- $23.455
- Previous close
- $23.43
- Volume
- 791.56K
- 1.05× average
- Average volume
- 751.83K
- Average daily volume
- Market cap
- 12.58B USD
- Beta
- 0.75
- Market reference 1
- 50-day average
- $23.9192
- -2.05% below average
- 200-day average
- $23.1578
- +1.18% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 21B EUR
- P/E (TTM)
- 12.09×
- P/B (TTM)
- 0.86×
- P/S (TTM)
- 0.55×
- EV / EBITDA
- 6.18×
- Earnings yield
- 8.29%
- Free cash flow yield
- 14.36%
- Dividend yield
- 3.71%
Profitability & efficiency
- Gross margin
- 26.36%
- Operating margin
- 10.69%
- Net margin
- 4.83%
- Return on equity
- 6.85%
- Return on assets
- 3.16%
- Return on invested capital
- 5.34%
Financial health
- Debt / equity
- 0.87×
- Current ratio
- 1.26×
- Altman Z-score
- 1.74
- Piotroski F-score
- 8 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 19.63B EUR | 19.34B EUR | 19.45B EUR | 19.4B EUR | 17.62B EUR |
| Cost of goods sold | 14.6B EUR | 14.58B EUR | 14.53B EUR | 14.5B EUR | 12.85B EUR |
| Gross profit | 5.03B EUR | 4.76B EUR | 4.93B EUR | 4.89B EUR | 4.77B EUR |
| Research and development | 157.98M EUR | 183.49M EUR | 231.97M EUR | 228.62M EUR | 220.78M EUR |
| Selling, general, and administrative | 3.03B EUR | 3.14B EUR | 3.2B EUR | 3.17B EUR | 2.77B EUR |
| Operating expenses | 3.2B EUR | 3.29B EUR | 3.56B EUR | 3.38B EUR | 2.92B EUR |
| Interest income | 69.61M EUR | 71.58M EUR | 88.22M EUR | 67.66M EUR | 73.17M EUR |
| Interest expense | 384.41M EUR | 407.04M EUR | 424.64M EUR | 360.14M EUR | 353.6M EUR |
| Depreciation and amortization | 1.5B EUR | 1.74B EUR | 1.75B EUR | 1.84B EUR | 1.62B EUR |
| Operating income | 1.83B EUR | 1.47B EUR | 1.37B EUR | 1.51B EUR | 1.85B EUR |
| Net income | 978.37M EUR | 537.91M EUR | 499M EUR | 673.41M EUR | 969.31M EUR |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 82%
- 9 beats, 1 miss, 1 met estimate
- Average EPS surprise
- +13.14%
- 11 comparable reports
- Latest EPS result
- 0.66
- Estimate 0.62 · Beat by 7.14%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$23.57
0.60% upsideRating distribution
21 ratingsRecent analyst actions
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$0.815
2025 complete year-2.3% since 2021
2026 partial: $0.8644
$0.8338
2,021
$0.7093
2,022
$0.6181
2,023
$0.6342
2,024
$0.815
2,025
$0.8644
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 22, 2026 | $0.8644Annual | May 22, 2026 | Jun 8, 2026 |
Dividend | May 23, 2025 | $0.815Annual | May 23, 2025 | Jun 6, 2025 |
Dividend | May 17, 2024 | $0.6342Annual | May 20, 2024 | Jun 3, 2024 |
Dividend | May 17, 2023 | $0.6181Annual | May 18, 2023 | Jun 1, 2023 |
Dividend | May 13, 2022 | $0.7093Annual | May 16, 2022 | May 27, 2022 |
Dividend | May 24, 2021 | $0.8338Annual | May 25, 2021 | Jun 7, 2021 |
Ex-dividend May 22, 2026
$0.8644
Annual
Record May 22, 2026 · Payment Jun 8, 2026
Ex-dividend May 23, 2025
$0.815
Annual
Record May 23, 2025 · Payment Jun 6, 2025
Ex-dividend May 17, 2024
$0.6342
Annual
Record May 20, 2024 · Payment Jun 3, 2024
Ex-dividend May 17, 2023
$0.6181
Annual
Record May 18, 2023 · Payment Jun 1, 2023
Ex-dividend May 13, 2022
$0.7093
Annual
Record May 16, 2022 · Payment May 27, 2022
Ex-dividend May 24, 2021
$0.8338
Annual
Record May 25, 2021 · Payment Jun 7, 2021
ETFs holding FMS
Funds reporting this stock among their holdings, ordered by reported position size.
Pzena U.S. Large Cap Value ETFPZLV2.04M2.90%59.37M USD0.60%$31.4899+1.36%
ActivePassive International Equity ETFAPIE718.55K0.06%953.79M USD0.45%$39.766+1.16%
Avantis International Equity ETFAVDE697.91K—19.1B USD0.23%$94.26+0.87%
Dimensional - International Core Equity Market ETFDFAI67.57K0.00%18.23B USD0.18%$43.35+0.81%
Dimensional - International Value ETFDFIV34.72K0.00%22.06B USD0.27%$58.31+0.88%
Avantis Responsible International Equity ETFAVSD14.53K—369.1M USD0.23%$82.994+0.86%
Pzena U.S. Large Cap Value ETFPZLV- Market value
- 2.04M
- Weight
- 2.90%
- AUM
- 59.37M USD
- Expense ratio
- 0.60%
- Price / 1D
- $31.4899+1.36%
ActivePassive International Equity ETFAPIE- Market value
- 718.55K
- Weight
- 0.06%
- AUM
- 953.79M USD
- Expense ratio
- 0.45%
- Price / 1D
- $39.766+1.16%
Avantis International Equity ETFAVDE- Market value
- 697.91K
- Weight
- —
- AUM
- 19.1B USD
- Expense ratio
- 0.23%
- Price / 1D
- $94.26+0.87%
Dimensional - International Core Equity Market ETFDFAI- Market value
- 67.57K
- Weight
- 0.00%
- AUM
- 18.23B USD
- Expense ratio
- 0.18%
- Price / 1D
- $43.35+0.81%
Dimensional - International Value ETFDFIV- Market value
- 34.72K
- Weight
- 0.00%
- AUM
- 22.06B USD
- Expense ratio
- 0.27%
- Price / 1D
- $58.31+0.88%
Avantis Responsible International Equity ETFAVSD- Market value
- 14.53K
- Weight
- —
- AUM
- 369.1M USD
- Expense ratio
- 0.23%
- Price / 1D
- $82.994+0.86%
Continue in GoAI
Research FMSresearch.disclaimer